Published on
September 21, 2021

Ketamine One Signs LOI with Veteran Services USA to Open Therapy Center

VANCOUVER, British Columbia, Sept. 21, 2021 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that it has recently signed a non-binding letter of interest (“LOI”) with Veteran Services USA (“VSUSA”) to lease approximately 5,000 square feet of space over an initial term of five years (the “Lease”) in Blue Island, Illinois (the “Blue Island Therapy Center”).

Located in the former MetroSouth Medical Center, the Blue Island Therapy Center is being planned to be part of a larger medical complex. Ketamine One will leverage its experience in ketamine-assisted therapies and innovative treatments, including integrating immersive virtual reality, towards creating a first-of-its-kind healing experience specifically for veterans suffering from post-traumatic stress disorder (“PTSD”) and other trauma-related challenges.

Pursuant to the LOI, Ketamine One will provide ketamine assisted therapy in other properties in the Veteran Services USA portfolio. The Company will be working with Veteran Services USA to identify further clinic locations for Ketamine One to develop within the growing network of Veteran Services USA properties.  

“We are very proud to be part of an important project such as this with Veteran Services USA, which will allow Ketamine One to showcase its innovative approach to care and treatment by addressing veterans’ unique needs. Given that between 11-20% of who served in Afghanistan, Iraq or Vietnam have PTSD in a given year, according to the US Department of Veterans Affairs, our Company sees an immediate need for its services and has a special opportunity to help heal countless veterans,” said Adam Deffett, Interim CEO of Ketamine One. “The Blue Island Therapy Center provides Ketamine One with another opportunity to demonstrate the broad application of its mental health platform as the Company continues to grow its operational footprint and aggregate medical clinics across North America,” added Mr. Deffett.

Additionally, the Company announces that it and Illumma LLC have mutually agreed to terminate the non-binding letter of intent previously announced on September 8, 2021. Ketamine One remains active in evaluating the acquisition of clinic assets in several US states and is focused on growing its network of existing clinics across North America.


Veteran Services USA (VSUSA) empowers Veterans and Seniors by offering services designed to build successful life transitions with access to workforce and independent housing; health services; and social service programs in communities across the United States. For transitioning Service Members, Veterans & Families, VSUSA seeks to provide educational programs featuring innovative training, counseling, and career connections through robust public-private partnerships, applying proven community and strength-based approaches to building resilience, treating trauma, and preventing suicide.


KetamineOne Capital Limited (formerly Myconic Capital Corp.) (NEO: MEDI) is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently, Ketamine One has a network of 15 clinics across North America, with plans to further consolidate the highly fragmented industry. The recent addition of KGK Science Inc. as the Company’s contract research division also places the company at the forefront of premium clinical research based on its 23-year history and extensive experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

On behalf of:


"Adam Deffett"
Adam Deffett, Interim CEO

For further information, please contact:

Nick Kuzyk, Investor Relations
Tel: 1-844-PHONE-K1 (1-844-746-6351)
Twitter: @KetamineOne

Notice Regarding Forward-Looking Information:

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and future prospects of the Company.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.